Janssen disappointed with second NICE no for Spravato
NICE has concerns with the evidence submitted but Janssen insists the nasal spray is a cost-effective use of NHS resources
Read More
Tag: nasal spray
New data highlights value of Janssen’s Spravato
The approval of the drug is a new way of treating adults with TRD that is unlike other treatment options in psychiatry.
Read More
Janssen files nasal spray for depression
Janssen has submitted a marketing application to the European Medicines Agency (EMA) seeking approval of investigational nasal spray esketamine for the treatment of major depressive disorder.
Read More
Phase III success for Janssen’s esketamine in treatment-resistant depression
Janssen has presented data from pivotal Phase III clinical studies backing use of esketamine spray in treatment-resistant depression.
Read More
- Transgene completes randomisation in phase 2 trial of tg4050
- Bayer wins MHRA approval for Kerendia in heart failure
- Oxford BioTherapeutics signs collaboration with Bristol Myers Squibb
- Kainova expands DT 7012 trial into Europe
- Amgen reports positive phase 3 results for subcutaneous TEPEZZA in thyroid eye disease
